Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.

Hasumi H, Baba M, Hasumi Y, Huang Y, Oh H, Hughes RM, Klein ME, Takikita S, Nagashima K, Schmidt LS, Linehan WM.

J Natl Cancer Inst. 2012 Nov 21;104(22):1750-64. doi: 10.1093/jnci/djs418. Epub 2012 Nov 12.

PMID:
23150719
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.

Schmidt LS.

Fam Cancer. 2013 Sep;12(3):357-64. doi: 10.1007/s10689-012-9574-y. Erratum in: Fam Cancer. 2013 Sep;12(3):365.

PMID:
23108783
[PubMed - indexed for MEDLINE]
3.

Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.

Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS.

J Natl Cancer Inst. 2008 Jan 16;100(2):140-54. doi: 10.1093/jnci/djm288. Epub 2008 Jan 8.

PMID:
18182616
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.

Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, Merino MJ, Linehan WM, Schmidt LS.

Mol Cancer. 2010 Jun 23;9:160. doi: 10.1186/1476-4598-9-160.

PMID:
20573232
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.

Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, Li Y, Khoo SK, Huang D, Qian CN, Zhao P, Dykema K, Zhang R, Cao B, Yang XJ, Furge K, Williams BO, Teh BT.

PLoS One. 2008;3(10):e3581. doi: 10.1371/journal.pone.0003581. Epub 2008 Oct 30. Erratum in: PLoS ONE. 2008;3(11). doi: 10.1371/annotation/0f06471c-1993-4144-b785-d58924ac0b5c. PLoS ONE. 2008;3(11). doi: 10.1371/annotation/136385d5-b241-4ecc-b31a-6dea3ebf3bc4. Dykyma, Karl [corrected to Dykema, Karl].

PMID:
18974783
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.

Hudon V, Sabourin S, Dydensborg AB, Kottis V, Ghazi A, Paquet M, Crosby K, Pomerleau V, Uetani N, Pause A.

J Med Genet. 2010 Mar;47(3):182-9. doi: 10.1136/jmg.2009.072009. Epub 2009 Oct 19.

PMID:
19843504
[PubMed - indexed for MEDLINE]
7.

Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein.

Takagi Y, Kobayashi T, Shiono M, Wang L, Piao X, Sun G, Zhang D, Abe M, Hagiwara Y, Takahashi K, Hino O.

Oncogene. 2008 Sep 11;27(40):5339-47. doi: 10.1038/onc.2008.261. Epub 2008 Jul 28.

PMID:
18663353
[PubMed - indexed for MEDLINE]
8.

Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.

Tee AR, Pause A.

Fam Cancer. 2013 Sep;12(3):367-72. doi: 10.1007/s10689-012-9576-9.

PMID:
23096221
[PubMed - indexed for MEDLINE]
9.

Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.

Lu X, Wei W, Fenton J, Nahorski MS, Rabai E, Reiman A, Seabra L, Nagy Z, Latif F, Maher ER.

Mol Cancer Ther. 2011 Jan;10(1):80-9. doi: 10.1158/1535-7163.MCT-10-0628.

PMID:
21220493
[PubMed - indexed for MEDLINE]
Free Article
10.

Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility.

Preston RS, Philp A, Claessens T, Gijezen L, Dydensborg AB, Dunlop EA, Harper KT, Brinkhuizen T, Menko FH, Davies DM, Land SC, Pause A, Baar K, van Steensel MA, Tee AR.

Oncogene. 2011 Mar 10;30(10):1159-73. doi: 10.1038/onc.2010.497. Epub 2010 Nov 8.

PMID:
21057536
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development.

Baba M, Keller JR, Sun HW, Resch W, Kuchen S, Suh HC, Hasumi H, Hasumi Y, Kieffer-Kwon KR, Gonzalez CG, Hughes RM, Klein ME, Oh HF, Bible P, Southon E, Tessarollo L, Schmidt LS, Linehan WM, Casellas R.

Blood. 2012 Aug 9;120(6):1254-61. doi: 10.1182/blood-2012-02-410407. Epub 2012 Jun 18.

PMID:
22709692
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.

Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM.

Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18722-7. doi: 10.1073/pnas.0908853106. Epub 2009 Oct 22.

PMID:
19850877
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.

Hong SB, Oh H, Valera VA, Baba M, Schmidt LS, Linehan WM.

PLoS One. 2010 Dec 29;5(12):e15793. doi: 10.1371/journal.pone.0015793.

PMID:
21209915
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).

Lu X, Boora U, Seabra L, Rabai EM, Fenton J, Reiman A, Nagy Z, Maher ER.

Oncogene. 2014 Feb 20;33(8):956-65. doi: 10.1038/onc.2013.27. Epub 2013 Feb 18.

PMID:
23416984
[PubMed - indexed for MEDLINE]
15.

Birt-Hogg-Dube syndrome is a novel ciliopathy.

Luijten MN, Basten SG, Claessens T, Vernooij M, Scott CL, Janssen R, Easton JA, Kamps MA, Vreeburg M, Broers JL, van Geel M, Menko FH, Harbottle RP, Nookala RK, Tee AR, Land SC, Giles RH, Coull BJ, van Steensel MA.

Hum Mol Genet. 2013 Nov 1;22(21):4383-97. doi: 10.1093/hmg/ddt288. Epub 2013 Jun 19.

PMID:
23784378
[PubMed - indexed for MEDLINE]
Free Article
16.

Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.

Klomp JA, Petillo D, Niemi NM, Dykema KJ, Chen J, Yang XJ, Sääf A, Zickert P, Aly M, Bergerheim U, Nordenskjöld M, Gad S, Giraud S, Denoux Y, Yonneau L, Méjean A, Vasiliu V, Richard S, MacKeigan JP, Teh BT, Furge KA.

BMC Med Genomics. 2010 Dec 16;3:59. doi: 10.1186/1755-8794-3-59.

PMID:
21162720
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.

Houweling AC, Gijezen LM, Jonker MA, van Doorn MB, Oldenburg RA, van Spaendonck-Zwarts KY, Leter EM, van Os TA, van Grieken NC, Jaspars EH, de Jong MM, Bongers EM, Johannesma PC, Postmus PE, van Moorselaar RJ, van Waesberghe JH, Starink TM, van Steensel MA, Gille JJ, Menko FH.

Br J Cancer. 2011 Dec 6;105(12):1912-9. doi: 10.1038/bjc.2011.463.

PMID:
22146830
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion.

Medvetz DA, Khabibullin D, Hariharan V, Ongusaha PP, Goncharova EA, Schlechter T, Darling TN, Hofmann I, Krymskaya VP, Liao JK, Huang H, Henske EP.

PLoS One. 2012;7(11):e47842. doi: 10.1371/journal.pone.0047842. Epub 2012 Nov 6.

PMID:
23139756
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Birt-Hogg-Dube syndrome: clinicopathological features of the lung.

Furuya M, Nakatani Y.

J Clin Pathol. 2013 Mar;66(3):178-86. doi: 10.1136/jclinpath-2012-201200. Epub 2012 Dec 8. Review.

PMID:
23223565
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome.

Benhammou JN, Vocke CD, Santani A, Schmidt LS, Baba M, Seyama K, Wu X, Korolevich S, Nathanson KL, Stolle CA, Linehan WM.

Genes Chromosomes Cancer. 2011 Jun;50(6):466-77. doi: 10.1002/gcc.20872. Epub 2011 Mar 15.

PMID:
21412933
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk